1. Finn, RS, Qin, S, Ikeda, M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New Engl J Med. 2020;382(20):1894-1905.
Google Scholar | Crossref | Medline2. Merle, P. The new immuno-oncology-based therapies and their perspectives in hepatocellular carcinoma. Cancers. 2021;13238.
Google Scholar3. Liu, X, Lu, Y, Qin, S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol. 2021;17(17):2243-2256.
Google Scholar | Crossref | Medline4. Iwamoto, H, Shimose, S, Noda, Y, et al. Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice. Cancers (Basel). 2021;13(11):2786.
Google Scholar | Crossref | Medline5. Wolchok, JD, Hoos, A, O’Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
Google Scholar | Crossref | Medline | ISI6. Nishino, M. Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment. J Immunother Cancer. 2016;4:30.
Google Scholar | Crossref | Medline7. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.
Google Scholar | Crossref | Medline | ISI8. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
Google Scholar | Crossref | Medline | ISI9. Kudo, M, Finn, RS, Qin, S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.
Google Scholar | Crossref | Medline10. Herbst, RS, Soria, J-C, Kowanetz, M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-567.
Google Scholar | Crossref | Medline | ISI11. Hodi, FS, Hwu, WJ, Kefford, R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510-1517.
Google Scholar | Crossref | Medline12. Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-1639.
Google Scholar | Crossref | Medline | ISI13. Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
Google Scholar | Crossref | Medline | ISI14. Ferris, RL, Blumenschein, G, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
Google Scholar | Crossref | Medline | ISI15. Park, HJ, Kim, KW, Pyo, J, et al. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology. 2020;297(1):87-96.
Google Scholar | Crossref | Medline16. Tanizaki, J, Hayashi, H, Kimura, M, et al. Report of two cases of pseudo-progression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer. 2016;102:44-48.
Google Scholar | Crossref | Medline17. Oxnard, GR, Morris, MJ, Hodi, FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104:1534-1541.
Google Scholar | Crossref | Medline18. Nishino, M, Giobbie-Hurder, A, Gargano, M, Suda, M, Ramaiya, NH, Hodi, FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:393643.
Google Scholar | Crossref19. Seymour, L, Bogaerts, J, Perrone, A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152.
Google Scholar | Crossref